DVT prophylaxis - direct antithrombins - all type of patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>DVT prophylaxis</strong> - direct antithrombins </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> RE-MOBILIZE (220mg), 2008 </a> <br> </td> <td> dabigatran etexilate 220 mg for 12-15 days <br>  <i>versus</i> <br> Enoxaparin 30 BID </td> <td> Total knee replacement </td> <td> follow-up 12-15 days, median 14d<br> n=862/876<br> <br> double blind <br> US, Canada, Mexico, UK </td> </tr> <tr> <td> <a href="index.html"> RE-MODEL (220mg), 2007 </a> <br> </td> <td> dabigatran etexilate 220 mg q.d. 6-10 days <br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. </td> <td> Total knee replacement </td> <td> follow-up 6-10 days, mean 8 days<br> n=694/699<br> <br> double blind <br> Europe, Australia, South Africa </td> </tr> <tr> <td> <a href="TRC_t6729.html"> RE-NOVATE (220mg), 2007 </a> <br> NCT00168818 </td> <td> dabigatran etexilate 220 mg q.d. for 28-35 days<br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. </td> <td> Total hip replacement </td> <td> follow-up 28-35 days, median 33d<br> n=1157/1162<br> Parallel groups<br> double blind <br> Europe, Australia, South Africa </td> </tr> <tr> <td> <a href="index.html"> RE-MODEL (150mg), 2007 </a> <br> </td> <td> dabigatran etexilate 150 mg q.d. for 6-10 days<br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. </td> <td> Total knee replacement </td> <td> follow-up 6-10 days, mean 8 days<br> n=708/699<br> Parallel groups<br> double blind <br> Europe, Australia, South Africa </td> </tr> <tr> <td> <a href="index.html"> RE-NOVATE (150mg), 2007 </a> <br> NCT00168818 </td> <td> dabigatran etexilate 150 mg q.d. 28-35 days <br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. </td> <td> Total hip replacement </td> <td> follow-up 28-35 days, median 33d<br> n=1174/1162<br> <br> double blind <br> Europe, Australia, South Africa </td> </tr> <tr> <td> <a href="index.html"> RE-MOBILIZE (150mg), 2008 </a> <br> </td> <td> dabigatran etexilate 150 mg q.d. for 12-15 days<br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. for 12-15 days </td> <td> Total knee replacement </td> <td> follow-up 12-15 days, median 14d<br> n=877/876<br> Parallel groups<br> double blind <br> US, Canada, Mexico, UK </td> </tr> <tr> <td> <a href="index.html"> BISTRO II (225mg bid), 2005 </a> <br> </td> <td> dabigatran etexilate 225 mg twice daily for 6�10 days<br>  <i>versus</i> <br> subcutaneous enoxaparin 40 mg once daily </td> <td> patients undergoing total hip or knee replacement </td> <td> follow-up <br> n=393/392<br> Parallel groups<br> double blind <br> Europe and South Africa (2 centres) </td> </tr> <tr> <td> <a href="TRC_t11113.html"> RE-NOVATE 2, 2010 </a> <br> NCT00657150 </td> <td> dabigatran 220mg once daily for 28-35 Days<br>  <i>versus</i> <br> enoxaparin 40mg subcutaneous </td> <td> patients undergoing total hip-replacement surgery </td> <td> follow-up 28-35 days (mean 32d)<br> n=1010/1003<br> Parallel groups<br> double-blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>RE-MOBILIZE (220mg), 2008 : </b> The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery. <i>J Arthroplasty 2008;:</i> [PMID 18534438] </p> <p> <b>RE-MODEL (220mg), 2007 : </b> Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, K�lebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, B�ller HROral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. <i>J Thromb Haemost 2007 Nov;5:2178-85</i> [PMID 17764540] </p> <p> <b>RE-NOVATE (220mg), 2007 : </b> Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, B�ller HRDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. <i>Lancet 2007;370:949-56</i> [PMID 17869635] </p> <p> <b>RE-MODEL (150mg), 2007 : </b> Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, K�lebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, B�ller HROral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. <i>J Thromb Haemost 2007;5:2178-85</i> [PMID 17764540] 10.1111/j.1538-7836.2007.02748.x </p> <p> <b>RE-NOVATE (150mg), 2007 : </b> Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, B�ller HRDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. <i>Lancet 2007;370:949-56</i> [PMID 17869635] </p> <p> <b>RE-MOBILIZE (150mg), 2008 : </b> Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JAOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. <i>J Arthroplasty 2009;24:1-9</i> [PMID 18534438] 10.1016/j.arth.2008.01.132 </p> <p> <b>BISTRO II (225mg bid), 2005 : </b> Eriksson BI, Dahl OE, B�ller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, K�lebo P, Reilly PA new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. <i>J Thromb Haemost 2005 Jan;3:103-11</i> [PMID 15634273] </p>